Evidence map›Paper›PMID 42228098›Full record

ArticleAnalytical chemistry2026

Distinguishing Ile/Leu Variant Ligands in the Immunopeptidome Using Hybrid EAD + CID Fragmentation (ExCID).

Mohammadreza Dorvash, Jeremy Potriquet, Pavel Ryumin, Rochelle Ayala, Ngoc Le, Ritchlynn Aranha, Patricia T Illing, Nathan P Croft, Sri H Ramarathinam, Anthony W Purcell

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Analytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mohammadreza DorvashBiomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia.ORCID 0000-0002-1935-9625
Jeremy PotriquetAB SCIEX, 495 Blackburn Road, Mount Waverley, VIC 3150, Australia.
Pavel RyuminAB SCIEX, 71 Four Valley Drive, Concord, Ontario L4K 4V8, Canada.
Rochelle AyalaBiomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia.
Ngoc LeBiomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia.
Ritchlynn AranhaBiomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia.
Patricia T IllingBiomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia.
Nathan P CroftBiomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia.
Sri H RamarathinamBiomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia.ORCID 0000-0002-2787-1282
Anthony W PurcellBiomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia.ORCID 0000-0003-0532-8331

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunopeptidomics aims to facilitate T-cell target discovery by analyzing human leukocyte antigen (HLA)-bound peptides using tandem mass spectrometry (MS/MS). MS/MS analysis of peptides conventionally relies on collision-induced dissociation (CID) of selected precursor ions. However, CID analysis of immunopeptides, owing to their diverse termini (nontryptic) and relatively short lengths (8- to 12-mer for class I HLA), can be challenging. It is impossible to differentiate isobaric amino acids, such as isoleucine and leucine sequence variants, which are frequent amino acids in the immunopeptidomes of many HLA allotypes. To address this, we leveraged the alternative fragmentation method, Electron-Activated Dissociation (EAD), and its CID-supplemented mode (EAD x CID, or ExCID) on the SCIEX ZenoTOF 7600+ system to characterize Ile/Leu sequence variants in the immunopeptidome. We first used a panel of seven synthetic Ile/Leu-substituted peptides and demonstrated that both EAD and ExCID efficiently generate variant-distinguishing

Indexed as

IsoleucineLeucinePeptidesAmino Acid SequenceHumansLigandsTandem Mass SpectrometryIsoleucineLeucineLigandsPeptides

Identifiers

PMID42228098
PMCPMC13277712

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.